ARA-290 (Cibinetide) — Neuropathic Pain and Autoimmune Research Guide
ARA-290 (Cibinetide) represents a novel approach to tissue protection and anti-inflammatory research — a non-hematopoietic erythropoietin analogue engineered to activate the innate repair receptor (IRR) for neuroprotective and anti-inflammatory effects without stimulating red blood cell production. Its FDA Fast-Track designation for autoimmune small fiber neuropathy and published Phase 2 human data make it one of the better-evidenced emerging research peptides in the anti-inflammatory category.
The EPO receptor paradox and the innate repair receptor
Erythropoietin (EPO) has two receptor systems: the homodimeric EpoR, which drives red blood cell production in the bone marrow, and the innate repair receptor (IRR) — a heterodimer of EpoR and the beta common receptor (betacR) — which mediates tissue protection and anti-inflammatory effects in the brain, neural tissue, heart, kidneys, and immune cells. These two receptor systems are expressed in different tissues and activated by different EPO concentrations. Native EPO at the concentrations required for tissue protection also produces erythrocytosis (excess red blood cells), hypertension, and increased thrombotic risk — adverse effects that have limited EPO's clinical applications to anemia treatment.
ARA-290 was designed to activate the IRR selectively without activating the homodimeric EpoR — achieving the tissue-protective and anti-inflammatory effects of EPO without the hematopoietic adverse effects. This was accomplished by engineering a peptide from EPO's helix B surface domain that contains the IRR binding epitope but lacks the homodimeric EpoR binding region.
Phase 2 human evidence: small fiber neuropathy in sarcoidosis
The most robust human evidence for ARA-290 comes from the Brines et al. (2014) Molecular Medicine study — a double-blind, placebo-controlled Phase 2 trial in 40 sarcoidosis patients with documented small fiber neuropathy (a painful neuropathic condition involving damage to the small unmyelinated nerve fibers that mediate pain and autonomic function). Patients receiving ARA-290 4mcg/kg for 28 days showed significant improvement in corneal nerve fiber density (a direct measure of small fiber regeneration), pain intensity scores, and quality of life metrics compared to placebo. The mechanistic basis — IRR activation promoting small fiber regeneration — was confirmed by the correlation between nerve density improvement and symptom reduction. This clinical evidence of neuroprotection and neural regeneration through IRR activation positioned ARA-290 for FDA Fast-Track designation for autoimmune small fiber neuropathy.
Anti-inflammatory and MCAS protocol applications
IRR receptors are expressed on macrophages, dendritic cells, and T-cells in addition to neural tissue — making ARA-290 relevant to immune modulation research beyond neuropathy. In inflammatory research, ARA-290 reduces macrophage pro-inflammatory cytokine production and promotes anti-inflammatory M2 macrophage polarization. For MCAS and inflammatory research protocols, ARA-290 adds an IRR-mediated neuroprotective and anti-inflammatory mechanism distinct from VIP's VPAC receptor mechanism, KPV's melanocortin receptor mechanism, and TA-1's Treg cell mechanism — making it an additive component in comprehensive inflammatory research protocols. It pairs particularly well with VIP in protocols where both neuropathic pain and mast cell activation are research endpoints. See the ARA-290 research profile and the MCAS Protocol guide.